Accelerate Diagnostics

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company's revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Type
Public
HQ
Tucson, US
Founded
2004
Employees
113 (est)+55%
Accelerate Diagnostics was founded in 2004 and is headquartered in Tucson, US

Accelerate Diagnostics Locations

Tucson, US
Castelldefels, ES

Accelerate Diagnostics Metrics

Accelerate Diagnostics Summary

Market capitalization

$1.05 B

Closing share price

$21.4
Accelerate Diagnostics's current market capitalization is $1.05 B.

Accelerate Diagnostics Financials

Accelerate Diagnostics's revenue is $147 K in FY, 2015 which is 20.49% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$48.3 K$122 K$147 K

Operating income

$-15.3 M$-31.5 M$-45.5 M

Net Income

$-15.3 M$-30.9 M$-45.5 M

Operating cash flow

$18 M$23.5 M$67 M

    Accelerate Diagnostics Market Value History

    Accelerate Diagnostics Online Presence

    Accelerate Diagnostics News

    Accelerate Diagnostics Company Life

    You may also be interested in